Fresenius Kabi Named “Supplier Partner of the Year 2023” by Vizient
Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the largest U.S. provider of healthcare performance improvement services. This recognition reflects Fresenius Kabi’s commitment to collaboration and innovation to enhance quality of care and patient safety.
This is Fresenius Kabi’s second time being named Vizient’s Supplier Partner of the Year.
October 04, 2023 · Fresenius Kabi
Brief News
EMA has accepted marketing authorization application for Ustekinumab biosimilar candidate of Fresenius Kabi and Formycon
Fresenius Kabi and its license partner Formycon announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for FYB202, an Ustekinumab biosimilar candidate. FYB202 references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
Fresenius Kabi is the commercialization partner. The acceptance of the MAA for review marks another milestone in the company’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
* Stelara® is a registered trademark of Johnson & Johnson
September 29, 2023 · Fresenius Kabi
Brief News
Fresenius supports people affected by the earthquake in Morocco and flooding in Libya
Fresenius makes available €500.000 for immediate release to the German Red Cross (Deutsches Rotes Kreuz e.V.) as assistance for disaster relief efforts to people affected by the recent earthquake in Morocco and the flooding in Libya. This cash donation will support direct disaster relief efforts on site. In addition, Fresenius remains committed to providing assistance with much needed medical products from its own product portfolio in crisis situations.
September 28, 2023 · Fresenius
Brief News
mAbxience and Abbott enter strategic partnership
mAbxience, a Fresenius Kabi majority-owned Group, today announced a strategic partnership with Abbott to commercialize several biosimilars focusing on oncology, women’s health and respiratory diseases in emerging markets including Latin America, Southeast Asia, the Middle East, and Africa. The first molecules are expected to be launched in 2025. mAbxience will manufacture the biosimilars in its state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for driving the clinical milestones for some of the molecules still undergoing development. The biosimilars will be commercialized by Abbott.
This strategic partnership strengthens mAbxience’s global presence and expands access to cutting-edge healthcare solutions in underserved regions.
September 20, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
The European Commission (EC) has approved Fresenius Kabi’s tocilizumab biosimilar Tyenne®*. It is the first tocilizumab biosimilar approved by the EC and Fresenius Kabi’s third approved biosimilar in Europe. This approval is another crucial milestone in the company’s Vision 2026 growth strategy.
* Tyenne® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
September 19, 2023 · Fresenius Kabi
Brief News
Key parameter for the 2024 DRG inflator for German hospitals set at 4.22%
The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2024 in Germany, has been set at 4.22%. Due to cost inflation, the rate of change will most likely mark the lower limit of the price increase for hospital treatments for 2024 in Germany. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.
September 18, 2023 · Fresenius Helios
Brief News
Fresenius Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System
Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients. VOA specializes in treating people with cancer and blood disorders. It is part of the national US Oncology network.
Fresenius Kabi and VOA have agreed to work together to integrate the Ivenix Infusion System with VOA’s electronic medical record (EMR) system.
Fresenius appoints Robert Möller to the Management Board
September 08, 2023 · Fresenius
Brief News
Progress on #FutureFresenius: Fitch revises the outlook of Fresenius SE & Co. KGaA from negative to stable, rating affirmed at BBB-
The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.
Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software
August 23, 2023 · Fresenius Medical Care
Brief News
Fresenius Kabi launches two generic drugs in the U.S.
Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Gadobutrol Injection, a gadolinium-based contrast agent for used in MRIs.1 It is the latest addition to Fresenius Kabi’s new radiology portfolio that offers hospitals a range of cost-effective contrast agents. The second product, Plerixafor Injection, a hematopoietic stem cell mobilizer is the newest addition to the company’s large generic injectable oncology medicine portfolio.
1 Gadobutrol Injection Package Insert, January 2023
August 09, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi and Formycon secure U.S. License Date for Ustekinumab biosimilar candidate
Fresenius Kabi and Formycon have entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed Ustekinumab biosimilar in the United States. Subject to regulatory approval, the settlement grants an entry date for FYB202 in the United States no later than April 15, 2025.
FYB202 is an Ustekinumab biosimilar candidate that references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
* Stelara® is a registered trademark of Johnson & Johnson
Progress on #FutureFresenius: Operating Companies showing consistent performance; Group simplification delivered
Michael Sen, CEO of Fresenius: “We are keeping up our pace and implement #FutureFresenius consistently and quickly. With all visible effect. Fresenius Helios and Fresenius Kabi delivered a good second quarter. Our Operating Companies are successful in their markets and bring innovations to our patients.
Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: “The second quarter makes evident that the execution against our strategic plan is fully on track. We are executing on our portfolio optimization, continuing to deliver on our FME25 program and are accelerating our turnaround activities.
August 02, 2023 · Fresenius Medical Care
Brief News
Fresenius Kabi’s tocilizumab biosimilar receives positive opinion on Marketing Authorization Application (MAA) for Europe
Fresenius Kabi’s tocilizumab biosimilar candidate, MSB11456, has received a positive recommendation for a marketing authorization from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). MSB11456 becomes the first tocilizumab biosimilar candidate to be granted a positive opinion by the CHMP for the treatment of several autoimmune diseases. This achievement marks a significant milestone in Fresenius Kabi’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
Fresenius Kabi announced today that its biosimilar candidate FKS518, a denosumab biosimilar candidate for the US reference product Prolia®*, successfully met its primary and secondary objectives in a recently conducted clinical trial on pharmacokinetic similarity. For more information, please see the website of Fresenius Kabi.
*Prolia® is a registered trademark of Amgen Inc.
July 12, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi launches two generic drugs in the U.S.
Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Ganirelix Acetate Injection, a generic fertility drug is part of the company’s expansion in women’s health. Ganirelix Acetate Injection is indicated for the inhibition of premature surges in luteinizing hormone, a chemical in the body that triggers reproductive processes such as ovulation. The second product is fentanyl citrate in a Simplist® ready-to-administer prefilled syringe presentation. The product is the only 100 mcg per 2 mL presentation available on the U.S. market in a manufacturer-prepared prefilled syringe.